Could Beta-Cell Stress Come Before Immune Attack in Type 1 Diabetes?

For decades, scientists have understood Type 1 diabetes as a disease where the immune system attacks insulin-producing beta cells in the pancreas. But a growing body of evidence suggests this story may be incomplete. A new review in Diabetes Research and Clinical Practice proposes an alternative: that stress within the beta cells themselves may come first, triggering the immune attack rather than simply being harmed by it.

This shift in thinking matters because understanding what starts the disease could help researchers develop better ways to prevent or treat it.

When beta cells experience stress—from problems in their energy factories (mitochondria) or protein-folding centers (endoplasmic reticulum)—they activate a cellular alarm system called cGAS-STING signaling. This alarm causes stressed beta cells to display more flags on their surface that the immune system recognizes as 'abnormal,' and to release chemicals that attract immune cells to the area.

At the same time, dying or distressed beta cells release substances that the immune system interprets as danger signals, and they may even create new targets (neoantigens) that the immune system learns to attack. All of this could happen before organized immune infiltration—the hallmark immune invasion we typically associate with Type 1 diabetes—is visible.

If beta-cell stress does trigger immune activation, the next step may be the formation of tertiary lymphoid structures (TLS)—organized immune tissue that forms in the pancreas over time. Think of these as long-term immune outposts that keep inflammation alive, even when the original trigger has passed.

Once these structures form, they may explain why Type 1 diabetes progresses steadily and why stopping immune activation in later stages of the disease has proven challenging. The immune system has essentially built a persistent neighborhood dedicated to attacking beta cells.

This framework offers a possible explanation for why current immune-targeted therapies—such as teplizumab, which delays disease onset—have limited durability. If the disease has already built these long-lasting immune structures, treating only the immune system later in the process may not be enough to stop it.

Importantly, researchers emphasize that direct evidence showing beta-cell stress comes before immune infiltration in people is still limited. The evidence is strongest in experimental models and lab studies of human tissue. However, the framework raises testable hypotheses that scientists can explore using existing resources, including patient registries like TrialNet and advanced tissue analysis techniques that can map cell behavior in pancreatic tissue in unprecedented detail.

This perspective does not overturn our current understanding of Type 1 diabetes, but rather integrates new observations into a more complete picture of how the disease develops. The next phase of research will focus on confirming whether beta-cell stress truly precedes immune attack in people living with or at risk for Type 1 diabetes, and whether interventions targeting early beta-cell stress could provide a new avenue for prevention or treatment.

Source: Diabetes research and clinical practice. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.